358371-23-0Relevant academic research and scientific papers
Ligand-free MCR for linking quinoxaline framework with a benzimidazole nucleus: A new strategy for the identification of novel hybrid molecules as potential inducers of apoptosis
Sunke, Rajnikanth,Babu, P. Vijaya,Yellanki, Swapna,Medishetti, Raghavender,Kulkarni, Pushkar,Pal, Manojit
, p. 6800 - 6805 (2014)
We report a true MCR involving the reaction of N-(prop-2-ynyl)quinoxalin-2- amine derivatives with 2-iodoanilines and tosyl azide in the presence of 10 mol% of CuI and Et3N in DMSO to afford the pre-designed hybrid molecules containing quinoxaline framework linked with a benzimidazole nucleus. The MCR proceeds in the absence of any ligand and/or lateral addition of the catalyst/base affording products within 30 min in good yields, some of which showed encouraging apoptosis inducing properties in zebrafish. This journal is the Partner Organisations 2014.
Synthesis and Antimicrobial Activity of Quinoxaline Based 1,2,3-Triazoles
Kumar, A. Kishore,Sunitha,Ramesh,Jalapathi
, p. 2386 - 2393 (2021/02/12)
Abstract: Synthesis and characterization of novel quinoxaline-1,2,3-triazole hybridheterocyclic derivatives have been carried out, and their antimicrobial activityhas been tested. Antibacterial and antifungal studies of the synthesizedcompounds have demonstrated high to moderate activity against the testedpathogens for most of those. Several products have been determined to be potentantimicrobial agents at concentrations of 75 and 100 μg/mL as compared to thestandard drug Gentamicin.
Ligand/PTC-free intramolecular Heck reaction: Synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo
Babu, P. Vijaya,Mukherjee, Soumita,Deora, Girdhar Singh,Chennubhotla, Keerthana Sarma,Medisetti, Raghavender,Yellanki, Swapna,Kulkarni, Pushkar,Sripelly, Shivashankar,Parsa, Kishore V. L.,Chatti, Kiranam,Mukkanti,Pal, Manojit
supporting information, p. 6680 - 6685 (2013/10/01)
A series of 1,3-disubstituted pyrrolo[2,3-b]quinoxalines has been designed for the potential inhibition of PDE4 without inhibiting luciferase. A ligand/PTC (phase transfer catalyst) free intramolecular Heck cyclization strategy was used to prepare these compounds, some of which showed significant inhibition of PDE4B (IC50 ≈ 5-14 μM) and growth inhibition of oral cancer cells (CAL 27) but not inhibition of luciferase in vitro. They also showed acceptable safety profiles but no apoptosis in zebrafish embryos.
